MCID: BRS049
MIFTS: 55

Breast Carcinoma in Situ malady

Cancer diseases category

Summaries for Breast Carcinoma in Situ

About this section
Sources:
32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast cancer and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is LIF (leukemia inhibitory factor), and among its related pathways are CREB Pathway and Malaria. The compounds cycloheximide and tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related mouse phenotypes are limbs/digits/tail and adipose tissue.

Aliases & Classifications for Breast Carcinoma in Situ

About this section
Sources:
8Disease Ontology, 56SNOMED-CT, 60UMLS, 39NCIt, 27ICD9CM, 25ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


Aliases & Descriptions:

breast carcinoma in situ 8
non-infiltrating carcinoma of breast 8
carcinoma in situ of breast 8


External Ids:

Disease Ontology8 DOID:8791
NCIt39 C3641
ICD9CM27 233.0
ICD1025 D05

Related Diseases for Breast Carcinoma in Situ

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Breast Benign Neoplasm
breast carcinoma in situ Familial Breast Cancer
Chek2-Related Susceptibility to Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Breast Cancer, Type 3
Breast Cancer, Early-Onset

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 152)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer30.7BRCA1, BRCA2
2ductal carcinoma in situ30.7BRCA1, BRCA2, CDH1, ERBB2, TP53
3ovarian cancer30.2BRCA1, BRCA2, MET, LIF, VEGFC, CDH1
4in situ carcinoma11.0
5breast apocrine carcinoma10.2
6poland syndrome10.2
7breast apocrine carcinoma in situ10.2
8female breast carcinoma10.1
9breast disease10.1
10pituitary adenoma10.0LIF
11malaria10.0LIF
12angiosarcoma10.0VEGFC
13dermatitis10.0LIF
14cervical intraepithelial neoplasia10.0VEGFC
15ischemia10.0VEGFC
16von hippel-lindau disease10.0MET
17chordoma10.0KRT19
18dilated cardiomyopathy10.0IL6ST
19nephritis10.0LIF
20breast-ovarian cancer, familial, 210.0BRCA2
21acute leukemia10.0IL6ST
22multiple endocrine neoplasia10.0BRCA2
23colon adenocarcinoma10.0CDH1
24gallbladder cancer10.0TP53
25neuroblastoma10.0TP53
26gastritis10.0TP53
27infertility10.0IL6ST, LIF
28prolactinoma10.0IL6ST, LIF
29proliferative diabetic retinopathy10.0MET
30ulcerative colitis10.0TP53
31teratoma10.0LIF
32pheochromocytoma10.0LIF, IL6ST
33uterine carcinosarcoma10.0ERBB2
34hepatoblastoma10.0LIF, MET
35leiomyosarcoma10.0TP53
36pemphigus vulgaris10.0CDH1
37werner syndrome10.0BRCA1
38gastrointestinal system disease10.0CDH1
39papilloma10.0TP53
40wilms tumor10.0VEGFC, BRCA2
41chondrosarcoma10.0KRT19, MET
42cystadenoma10.0BRCA1, VEGFC
43hereditary diffuse gastric cancer10.0CDH1
44malignant mesothelioma10.0CDH1, MET
45bilateral breast cancer10.0BRCA1, BRCA2
46neutropenia10.0ERBB2, LIF
47aplastic anemia10.0BRCA2, BRCA1
48laryngeal benign neoplasm10.0TP53, VEGFC
49liver cirrhosis10.0TGFB1
50biliary tract neoplasm10.0MET, ERBB2

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Clinical Features for Breast Carcinoma in Situ

About this section

Drugs & Therapeutics for Breast Carcinoma in Situ

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Breast Carcinoma in Situ

Drug clinical trials:

Search ClinicalTrials for Breast Carcinoma in Situ

Search NIH Clinical Center for Breast Carcinoma in Situ

Search CenterWatch for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

About this section

Anatomical Context for Breast Carcinoma in Situ

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Breast Carcinoma in Situ:

32
Breast, Lymph node, Testes, Smooth muscle, Cervix

Animal Models for Breast Carcinoma in Situ or affiliated genes

About this section
Sources:
36MGI
See all sources

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

36 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537110.2BRCA2
2MP:000537510.1LIF
3MP:00053919.9LIF
4MP:00053809.6KRT19, ERBB2
5MP:00053699.5TP53, TGFB1, MET
6MP:00053769.4IL6ST, BRCA1, BRCA2, LIF
7MP:00036318.4IL6ST, LIF, ERBB2, TGFB1, KRT19
8MP:00053888.2TP53, TGFB1, ERBB2, IL6, BRCA1, LIF
9MP:00053708.2LIF, IL6, IL6ST, TP53, TGFB1, MET
10MP:00053908.1IL6ST, IL6, LIF, BRCA2, BRCA1, KRT19
11MP:00053977.9BRCA1, BRCA2, LIF, IL6, IL6ST, TP53
12MP:00020067.8KRT19, TGFB1, ERBB2, SDC1, MET, CDH1
13MP:00053897.6TGFB1, BRCA2, BRCA1, LIF, CDH1, KRT19
14MP:00053797.4BRCA2, BRCA1, IL6, IL6ST, KRT19, TP53
15MP:00028737.4CDH1, BRCA1, BRCA2, MET, TP53, ERBB2
16MP:00053867.4IL6, OSM, LIF, ERBB2, TP53, BRCA2
17MP:00053876.8CDH1, TGFB1, SDC1, TP53, IL6ST, IL6
18MP:00053856.5CDH1, KRT19, ERBB2, TP53, IL6ST, IL6
19MP:00053816.5TP53, ERBB2, TGFB1, BRCA1, BRCA2, MET
20MP:00107716.5OSM, BRCA1, TP53, BRCA2, KRT19, IL6
21MP:00053786.4BRCA1, TP53, ERBB2, LIF, IL6ST, MET
22MP:00053845.9KRT19, BRCA1, BRCA2, MET, CDH1, LIF
23MP:00107685.7BRCA1, BRCA2, MET, LIF, TGFB1, IL6

Publications for Breast Carcinoma in Situ

About this section
Sources:
50PubMed
See all sources

Articles related to Breast Carcinoma in Situ:

(show top 50)    (show all 608)
idTitleAuthorsYear
1
Predictors of Treatment with Mastectomy, Use of Sentinel Lymph Node Biopsy and Upstaging to Invasive Cancer in Patients Diagnosed with Breast Ductal Carcinoma In situ (DCIS) on Core Biopsy. (24046105)
2014
2
Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. (24121179)
2014
3
Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast. (24011572)
2013
4
Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens. (23199579)
2013
5
Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. (22795363)
2012
6
In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas. (23028444)
2012
7
The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy. (22205445)
2012
8
Case report: ductal carcinoma in situ in the male breast. (23056988)
2012
9
Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy. (22445178)
2012
10
A novel, patient-specific mathematical pathology approach for assessment of surgical volume: application to ductal carcinoma in situ of the breast. (21988888)
2011
11
Massive myoepithelial proliferation (myoepitheliosis) with lumpy deposits of basement membrane material closely associated with apocrine adenosis and ductal carcinoma in situ of the breast. (21951673)
2011
12
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. (21476105)
2011
13
Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up. (21084964)
2011
14
Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer: Data Points # 15 (23115801)
2011
15
Radiographic features for triple negative ductal carcinoma in situ of the breast. (21465228)
2011
16
Multicentric adenomyoepithelioma of the breast with atypia and associated ductal carcinoma in situ. (20604795)
2010
17
Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. (19675453)
2009
18
The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. (19309393)
2009
19
Examination of specimens from patients with ductal carcinoma in situ of the breast using large-format histology sections. (19722732)
2009
20
Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. (19207950)
2009
21
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. (18665169)
2008
22
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). (18317962)
2008
23
Expression patterns of lymphangiogenic and angiogenic factors in a model of breast ductal carcinoma in situ. (17936419)
2007
24
Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. (16807982)
2006
25
Ductal carcinoma in situ of the breast with osteoclast-like giant cells. (16613333)
2006
26
Ovarian cyst torsion and extreme ovarian stimulation in a premenopausal patient treated with tamoxifen for ductal carcinoma in situ of the breast. (17000228)
2006
27
CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. (16828238)
2006
28
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. (16707453)
2006
29
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. (15788662)
2005
30
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. (16280056)
2005
31
HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. (15899781)
2005
32
HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. (15696127)
2005
33
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. (14717665)
2004
34
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. (12874968)
2003
35
Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. (12527916)
2003
36
The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. (12927035)
2003
37
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. (11912139)
2002
38
Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism. (11245337)
2001
39
Breast carcinoma in situ: risk factors and screening patterns. (11734598)
2001
40
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. (11238049)
2001
41
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. (11344235)
2001
42
Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. (9935151)
1999
43
Messenger ribonucleic acid in situ hybridization analysis of estrogen receptors alpha and beta in human breast carcinoma. (10022453)
1999
44
Trends of in situ carcinoma of the breast in Vaud, Switzerland. (9291813)
1997
45
Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma. (7910618)
1994
46
Surgeon's dilemma: in situ carcinoma of the female breast with special reference to limited surgery. (8435184)
1993
47
Breast carcinoma in situ. (2535929)
1989
48
The growth pattern of in situ carcinoma in the female breast. (2851304)
1988
49
Atypical small-cell dysplasia and in situ carcinoma of the breast: incidence of subsequent invasive carcinoma. (1084467)
1976
50
Atypical small-cell dysplasia and in situ carcinoma of the breast: an analysis of subsequently developing ipsilateral invasive carcinomas. (1082977)
1976

Genetic Variations for Breast Carcinoma in Situ

About this section

Expression for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
51QIAGEN, 29KEGG, 12EMD Millipore, 59Tocris Bioscience, 53Reactome, 37NCBI BioSystems Database, 52R&D Systems, 55SinoBiological
See all sources

Pathways related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 55)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.2VEGFC
210.0SDC1
310.0SDC1
4
Hide members
10.0VEGFC, MET
5
Hide members
9.8MET, IL6
69.7TP53, BRCA1
79.7TGFB1, IL6
8
Hide members
9.7TP53, ERBB2
9
Hide members
9.6VEGFC, ERBB2, MET
10
Hide members
9.6SDC1, TGFB1
11
Hide members
9.6TGFB1, SDC1
129.6LIF, VEGFC, IL6
13
Hide members
9.6VEGFC, CDH1, ERBB2
149.5MET, CDH1, ERBB2
159.4TP53, BRCA2, BRCA1
16
Hide members
9.4BRCA2, BRCA1, TP53
17
DNA damage Role of Brca1 and Brca2 in DNA repair
Hide members
9.4BRCA2, BRCA1, TP53
189.4ERBB2, MET, TP53
199.4TP53, ERBB2, CDH1
209.3TGFB1, IL6ST, LIF
219.3MET, TGFB1, SDC1
229.2TGFB1, TP53, IL6
239.2IL6, IL6ST, ERBB2
24
Hide members
9.2TGFB1, VEGFC, MET, IL6
25
Cytokine production by Th17 cells in CF (Mouse model)
9.2IL6, IL6ST, TGFB1
26
Hide members
9.2IL6, TGFB1, IL6ST
279.2TGFB1, IL6, IL6ST
289.2CDH1, TP53, VEGFC, BRCA1
299.1MET, BRCA1, TP53, ERBB2
309.1BRCA1, TP53, CDH1, BRCA2
319.1LIF, OSM, IL6ST
32
Hide members
9.1CDH1, ERBB2, TP53, MET
33
Hide members
9.0TGFB1, BRCA2, ERBB2, TP53
34
Translation Insulin regulation of translation
Hide members
9.0ERBB2, TGFB1, IL6ST, MET
35
Hide members
9.0IL6ST, ERBB2, LIF, IL6
36
Immune response Oncostatin M signaling via JAK-Stat in human cells
Hide members
8.9IL6ST, IL6, OSM
37
G-protein signaling Ras family GTPases in kinase cascades (scheme)
Hide members
8.9TP53, IL6ST, OSM
38
Transcription Androgen Receptor nuclear signaling
Hide members
8.8IL6ST, ERBB2, TGFB1, IL6
398.7TP53, ERBB2, BRCA2, BRCA1, TGFB1
408.7TP53, IL6ST, IL6, TGFB1
418.5ERBB2, SDC1, MET, TP53, TGFB1
42
Hide members
8.4MET, LIF, VEGFC, ERBB2, TGFB1, OSM
438.3LIF, TGFB1, IL6ST, IL6, OSM
448.3TP53, ERBB2, IL6, CDH1, BRCA2, TGFB1
458.2MET, BRCA1, OSM, TP53, IL6, VEGFC
46
Hide members
8.1TP53, TGFB1, ERBB2, IL6, VEGFC, BRCA2
47
Hide members
7.6TGFB1, LIF, VEGFC, IL6, IL6ST, ERBB2
48
Hide members
7.5ERBB2, OSM, MET, LIF, VEGFC, IL6
49
Hide members
7.4OSM, IL6ST, ERBB2, LIF, IL6, VEGFC
50
Hide members
6.9TGFB1, BRCA1, OSM, MET, TP53, ERBB2

Compounds for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
44Novoseek, 49PharmGKB, 28IUPHAR, 11DrugBank, 24HMDB, 59Tocris Bioscience, 2BitterDB
See all sources

Compounds related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 120)
idCompoundScoreTop Affiliating Genes
1cycloheximide4410.3BRCA1, BRCA2
2tamoxifen44 49 28 1112.8TGFB1, ERBB2, CDH1
3pge2449.7CDH1, TGFB1, MET, VEGFC
4estradiol44 11 2411.6VEGFC, OSM, BRCA2
5il 11449.5IL6, LIF, OSM
6indole-3-carbinol449.5BRCA2, CDH1, BRCA1, TP53
7methylcellulose449.4IL6, LIF, TGFB1, CDH1
8heparin44 28 11 2412.3ERBB2, CDH1, LIF, BRCA1
94-hydroxytamoxifen449.3TGFB1, BRCA2, ERBB2, BRCA1
10vitamin d449.3IL6ST, IL6, ERBB2, MET
11depsipeptide449.1TP53, OSM, CDH1, LIF
12bleomycin44 1110.1BRCA1, BRCA2, TP53, TGFB1
13bortezomib44 1110.0BRCA1, TP53, ERBB2, IL6
145fluorouracil449.0TP53, ERBB2, CDH1, BRCA1, LIF
15matrigel449.0LIF, BRCA2, CDH1, KRT19, MET
16ifn-alpha448.9IL6, LIF, OSM, IL6ST
17pdtc448.9MET, TGFB1, TP53, IL6
18carboplatin44 49 1110.9TP53, ERBB2, LIF, BRCA1
19tgf beta1448.8OSM, TGFB1, IL6, CDH1, LIF
20herbimycin a44 599.8CDH1, ERBB2, MET, IL6, OSM
21methotrexate44 49 1110.8CDH1, BRCA2, BRCA1, TGFB1, IL6, ERBB2
22curcumin448.8CDH1, TGFB1, TP53, ERBB2, IL6
23docetaxel44 49 59 1111.8BRCA2, TGFB1, BRCA1, TP53, ERBB2, CDH1
24etoposide44 49 59 1111.8TGFB1, CDH1, BRCA2, BRCA1, TP53, ERBB2
25doxorubicin44 49 1110.8BRCA1, MET, CDH1, ERBB2, TGFB1, TP53
26p002448.5BRCA1, MET, CDH1, KRT19, BRCA2, ERBB2
27proline448.5TP53, CDH1, BRCA2, BRCA1, IL6ST, MET
28phosphotyrosine448.5OSM, MET, CDH1, IL6ST, ERBB2, BRCA1
29ly294002448.5CDH1, TP53, IL6, ERBB2, TGFB1, VEGFC
30pd 98,059448.4TGFB1, IL6, MET, OSM, CDH1, VEGFC
31ribonucleic acid448.4TGFB1, IL6ST, KRT19, VEGFC, MET, LIF
32agar448.3OSM, BRCA1, MET, LIF, CDH1, IL6ST
33hyaluronic acid44 249.2CDH1, OSM, IL6, KRT19, TGFB1
34oligonucleotide448.2BRCA1, MET, IL6ST, TGFB1, TP53, VEGFC
35steroid448.2OSM, LIF, BRCA1, BRCA2, KRT19, ERBB2
36lactate448.1IL6, LIF, CDH1, TGFB1, ERBB2, KRT19
37dexamethasone44 49 28 1111.1IL6ST, IL6, LIF, OSM, CDH1, TGFB1
38paclitaxel44 49 119.8TP53, LIF, BRCA1, BRCA2, ERBB2, TGFB1
39phosphatidylinositol447.7VEGFC, IL6ST, BRCA1, OSM, MET, ERBB2
40alanine447.7TGFB1, ERBB2, BRCA1, IL6ST, IL6, CDH1
41testosterone44 59 11 2410.7BRCA2, IL6, LIF, VEGFC, CDH1, ERBB2
42genistein44 28 59 2 11 2412.6ERBB2, IL6ST, IL6, CDH1, LIF, MET
43cisplatin44 49 59 1110.5BRCA1, BRCA2, MET, CDH1, KRT19, ERBB2
44serine447.3BRCA1, TGFB1, OSM, LIF, CDH1, IL6ST
45paraffin447.3KRT19, ERBB2, VEGFC, TGFB1, CDH1, TP53
46progesterone44 59 28 11 2411.1BRCA1, BRCA2, MET, LIF, ERBB2, IL6ST
47thymidine44 247.9BRCA1, TGFB1, TP53, KRT19, BRCA2, VEGFC
48tyrosine446.8OSM, MET, VEGFC, LIF, CDH1, IL6
49retinoic acid44 247.0KRT19, TGFB1, TP53, IL6ST, IL6, CDH1
50vegf446.0TGFB1, TP53, KRT19, IL6ST, IL6, CDH1

GO Terms for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 receptor complexGO:0058969.7IL6ST, IL6
2oncostatin-M receptor complexGO:0059009.4OSM, IL6ST
3focal adhesionGO:0059259.1BRCA1, CDH1, SDC1
4protein complexGO:0432348.8SDC1, TP53, BRCA2, BRCA1
5extracellular regionGO:0055768.1VEGFC, MET, IL6, IL6ST, SDC1, TGFB1
6extracellular spaceGO:0056158.1LIF, VEGFC, IL6, IL6ST, TGFB1, OSM

Biological processes related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show all 32)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:07168110.2BRCA1, CDH1
2leukemia inhibitory factor signaling pathwayGO:04886110.0IL6ST, LIF
3tyrosine phosphorylation of Stat3 proteinGO:0425039.9LIF, OSM
4negative regulation of neuroblast proliferationGO:0074069.9TGFB1, TP53
5positive regulation of tyrosine phosphorylation of Stat1 proteinGO:0425119.9LIF, IL6ST
6positive regulation of astrocyte differentiationGO:0487119.9IL6ST, LIF
7positive regulation of histone deacetylationGO:0310659.9TP53, TGFB1
8negative regulation of meiosisGO:0458359.9LIF, OSM
9negative regulation of cell-cell adhesionGO:0224089.8TGFB1, CDH1
10positive regulation of histone acetylationGO:0350669.8TGFB1, BRCA1
11DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:0069789.8BRCA1, TP53, BRCA2
12interleukin-6-mediated signaling pathwayGO:0701029.8IL6ST, IL6
13positive regulation of blood vessel endothelial cell migrationGO:0435369.7TGFB1, VEGFC
14double-strand break repairGO:0063029.7BRCA1, TP53, BRCA2
15positive regulation of cell cycle arrestGO:0711589.7BRCA1, TP53, TGFB1
16positive regulation of tyrosine phosphorylation of Stat3 proteinGO:0425179.7LIF, IL6, IL6ST
17negative regulation of hormone secretionGO:0468889.6OSM, IL6, LIF
18positive regulation vascular endothelial growth factor productionGO:0105759.6IL6ST, TGFB1
19positive regulation of cell divisionGO:0517819.6TGFB1, VEGFC, OSM
20positive regulation of MAPK cascadeGO:0434109.5OSM, LIF, IL6
21positive regulation of epithelial cell proliferationGO:0506799.5ERBB2, IL6, VEGFC, TGFB1
22response to X-rayGO:0101659.4BRCA2, TP53
23response to drugGO:0424939.4VEGFC, TGFB1, IL6, CDH1
24positive regulation of acute inflammatory responseGO:0026759.3IL6ST, IL6, OSM
25positive regulation of peptidyl-serine phosphorylationGO:0331389.2IL6, TGFB1, LIF, OSM
26positive regulation of peptidyl-tyrosine phosphorylationGO:0507319.1LIF, OSM, TP53, IL6
27cell proliferationGO:0082838.9MET, ERBB2, OSM, TP53
28negative regulation of cell proliferationGO:0082858.7TGFB1, TP53, IL6, OSM, LIF
29positive regulation of transcription, DNA-dependentGO:0458938.7BRCA1, TGFB1, TP53, IL6, CDH1, BRCA2
30modulation by virus of host morphology or physiologyGO:0190488.4TGFB1, KRT19, TP53, IL6ST
31positive regulation of cell proliferationGO:0082848.4OSM, LIF, VEGFC, IL6, IL6ST, TGFB1
32positive regulation of transcription from RNA polymerase II promoterGO:0459448.2MET, TGFB1, LIF, IL6, OSM, TP53

Molecular functions related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 receptor bindingGO:0051389.5IL6, IL6ST
2protein phosphatase bindingGO:0199039.2ERBB2, CDH1, MET
3growth factor activityGO:0080838.6OSM, LIF, VEGFC, IL6, TGFB1
4protein bindingGO:0055155.9BRCA1, BRCA2, VEGFC, CDH1, IL6ST, KRT19

Products for genes affiliated with Breast Carcinoma in Situ

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Breast Carcinoma in Situ

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet